Pfizer vs PhonePe

Pfizer Market Stance

Pfizer stands as one of the defining institutions of modern pharmaceutical history — a company that has shaped global medicine through blockbuster drugs, transformative acquisitions, and most recently, the fastest vaccine development in human history. Founded in Brooklyn, New York in 1849 by cousins Charles Pfizer and Charles Erhart as a fine chemicals business, Pfizer spent its first century as a competent but unremarkable industrial chemicals manufacturer. The company's trajectory changed permanently during World War II when the US government commissioned Pfizer to mass-produce penicillin using a deep-tank fermentation process that the company had pioneered — an achievement that established Pfizer's manufacturing capability as a strategic national asset and demonstrated that scale and process innovation could be as powerful as discovery science. The post-war era saw Pfizer transition systematically from a chemicals manufacturer into a pharmaceutical research company. The discovery of Terramycin (oxytetracycline) in 1950 — a broad-spectrum antibiotic developed through Pfizer's own research program — was the first breakthrough that demonstrated the company could originate valuable medicines rather than simply manufacture compounds discovered elsewhere. This shift toward proprietary drug discovery, combined with aggressive international expansion through the 1950s and 1960s, established the template for Pfizer's modern business model. The late 1990s and 2000s were Pfizer's blockbuster era. Lipitor (atorvastatin), launched in 1997 after the acquisition of Warner-Lambert in 2000 brought it fully under Pfizer's commercial control, became the best-selling drug in pharmaceutical history — generating peak annual revenues exceeding $13 billion. Viagra (sildenafil), Norvasc (amlodipine), Celebrex (celecoxib), Zoloft (sertraline), and Lyrica (pregabalin) formed a portfolio of blockbusters that made Pfizer the world's largest pharmaceutical company by revenue for much of the 2000s. This concentration in small-molecule blockbusters was also the seed of Pfizer's greatest strategic crisis: as these drugs lost patent protection through the 2010s, the resulting revenue cliff required either transformative acquisition or deep pipeline investment to bridge. Pfizer's response to patent expiry was primarily acquisitional. The Wyeth acquisition in 2009 for $68 billion brought biologics capability (including the Prevnar pneumococcal vaccine franchise, which became one of the most valuable vaccine assets in history), consumer healthcare products, and animal health operations. The Hospira acquisition in 2015 for $17 billion added sterile injectable hospital products and biosimilars capability. The acquisition of Allergan's generics business (Actavis) in 2016 for $17 billion — initially structured as a tax inversion that was subsequently abandoned — reflected the continuing search for revenue to offset patent losses, though the eventual Upjohn spinoff and combination with Mylan to form Viatris in 2020 ultimately disposed of the generics strategy. The COVID-19 pandemic represented Pfizer's most consequential moment since the penicillin era. The partnership with BioNTech, a German biotech that had developed mRNA vaccine technology over a decade, produced Comirnaty — a COVID-19 vaccine that received Emergency Use Authorization in December 2020 and full FDA approval in August 2021, and which was administered to hundreds of millions of people globally. The speed of development — under 12 months from sequence to authorization — was unprecedented and demonstrated that the regulatory, manufacturing, and distribution infrastructure of a major pharmaceutical company, combined with a breakthrough technology platform, could operate at a scale and pace that the medical establishment had considered impossible. Financially, the COVID products transformed Pfizer's economics. Comirnaty and Paxlovid (the COVID-19 antiviral oral treatment) generated combined revenues exceeding $56 billion in 2022 alone — revenues that dwarfed Pfizer's pre-pandemic annual totals and created a capital war chest that management deployed aggressively through acquisitions. The Arena Pharmaceuticals acquisition (2022, $6.7 billion), Biohaven acquisition (2022, $11.6 billion), ReViral acquisition (2022, $525 million), GBT acquisition (2022, $5.4 billion), Seagen acquisition (2023, $43 billion), and Nuvax option (2023) represented a sustained acquisition campaign designed to rebuild the revenue base for the post-COVID normalization period. The normalization arrived faster and more severely than most models anticipated. COVID vaccine and antiviral revenues collapsed as global vaccination coverage reached saturation and the acute phase of the pandemic receded. Pfizer's 2023 revenues fell to approximately $58 billion from the 2022 peak of $100 billion — a 42% decline in a single year that required a major cost restructuring program ($3.5 billion target) and a fundamental reassessment of the acquisition strategy's timing and execution.